skip to main
|
skip to sidebar
Blog Archives: Nov 2004 - present
Special items: Ovarian Cancer and Us blog best viewed in Firefox
DARA BioSciences Announces New Analysis of Patient Self-Reported Diary Results in a Phase 2a Clinical Trial of KRN5500 in Patients With Cancer and Neuropathic Pain - Drugs.com
http://tinyurl.com/7tmt942
"....Previous analyses of the study data were based predominantly on
patient-reported Numeric Rating Scale (NRS) pain scores collected
by healthcare professionals in a clinic setting during weekly
visits, whereas this new analysis focused specifically on
self-reported daily pain scores from patients' diaries. Responders
in this analysis were defined as patients attaining a
clinically-meaningful (at least 20%) improvement in mean NRS scores
from baseline within any given week. Of the 12 patients who
received KRN5500 in this 19-patient trial, 7 (58%) were classified
as responders. Further, 5 of the 7 (71%) showed sustained pain
relief over several weeks. Of the 7 patients who received placebo,
none were responders. Therefore, the new analysis showed a temporal
consistency of pain relief in a larger fraction of patients than
had been noted in the earlier analysis of weekly clinic-reported
pain. These findings are impressive since patients enrolled in this
proof-of-concept trial had unrelenting pain at baseline despite the
concomitant use of other approved analgesic agents........
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.